Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide.
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …

Background. When the bivalent and the quadrivalent HPV vaccines were marketed they
were presented as having comparable efficacy against cervical cancer. Differences between …

Human papillomavirus (HPV) is the most common sexually transmitted disease, worldwide.
Primary prevention thorough vaccination si able to reduce the burden of HPV-related …

Cervical cancer may be substantially prevented by human papillomavirus (HPV)
vaccination. The two most common oncogenic HPV types causing 70% of all cervical …

The human papillomavirus (HPV) represents one of the most common sexually transmitted
infections and it has been related to cervical cancer. The HPV vaccines prevent infection …

BACKGROUND: Current randomized clinical trials have shown that the quadrivalent human
papillomavirus (HPV) vaccine can reduce the morbidity of precancerous lesions associated …

Cervical cancer is one of the most common cancers in women aged 15-44 years in the
world, with more than three-quarters of cases diagnosed at a locally advanced clinical stage …

Cervical cancer incidence and mortality have decreased in high-income countries, but low-
and middle-income countries continue to bear a significant burden from the disease. Human …

Introduction: Safety and efficacy of prophylactic HPV vaccines against HPV infection and
associated cervical cancers and precursors is well documented in the literature; however …

Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a
necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could …